This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Acceleron Pharma, Inc.
Drug Names(s): ACE-041, Dalantercept
Dalantercept is a soluble form of activin receptor-like kinase (ALK1) that binds to bone morphogenetic protein-9 (BMP9) and BMP10 thereby competitively inhibiting activation of endogenous ALK1 and subsequent angiogenesis. Specifically, dalantercept is a fusion protein consisting of the extracellular domain of human ALK1 linked to the Fc portion of human IgG1.
Note that in preclinical studies, a murine version of dalantercept, RAP-041, was evaluated.
Additional information available to subscribers only: